WuXi AppTec, Laboratory Testing Division

🎉 The 2024 Annual Meeting of the American College of Toxicology is just around the corner, and we’re thrilled to be a part of it! Join us in Austin, TX, and stop by Booth 500 to connect with the WuXi AppTec Lab Testing team. Don’t miss this chance to meet industry experts and learn how we can support your drug development efforts, including details on our new imaging center. Be sure to add our Exhibitor Hosted Session to your calendar: 📋 Maximizing Outcomes Through Multi-Site Study Collaboration 🎤 Sue McPherson, Executive Director, Toxicology, WuXi AppTec 🗓️ Tuesday, November 19th | 12:00 pm-12:55 pm 📍 Level 2, Room 203 Plus, look for our two informative poster presentations on the show floor, and treat yourself at our in-booth Gelato Bar on Monday from 5:00-6:00 pm. 🍦 Get more details here: https://hubs.li/Q02WtGsv0 #ACT2024 #Toxicology #DrugDevelopment

Facing low bioavailability and poor stability in your peptide drugs? Discover actionable strategies to optimize their DMPK properties for improved development outcomes. Join WuXi AppTec and AAPS for an exclusive webinar, where you'll gain the insights needed to enhance peptide permeability and stability. Accelerate your journey from screening to IND submission with proven DMPK strategies. 📅 Date: November 6, 2024 🕒 Time: 11:15 AM - 11:45 AM EST 🔗 Register here: https://hubs.li/Q02Vm_540 (free to everyone, but you’ll need to register a free account at AAPS) #PeptideDrugs #DMPK #PharmaResearch #DrugDevelopment #Bioavailability #PharmaceuticalScience #INDSubmission

WuXi AppTec’s team of researchers recently took a closer look at the FOB test, an important tool in determining neurotoxic effects. The findings will support safer drug development and provide a framework for future studies. Read more: https://hubs.li/Q02T1wYs0 #innovation #neurotoxicity #drugreseach

Does your testing partner use automated liquid handling workstations? In vitro ADME testing automation provides three distinct advantages, accelerating your candidate's path to market. Learn more: https://hubs.li/Q02ShM6q0 #adme #dmpk #drugdevelopment #pharmaceuticals #innovation

Radionuclide Drug Conjugates (RDCs) represent a paradigm shift in oncology, offering the dual benefits of precise tumor targeting and diagnostic capabilities, all while minimizing the side effects typically associated with cancer treatment. As more RDCs enter clinical trials and the pipeline for approval grows, we are on the brink of a new era in cancer care. What are the challenges they face? https://hubs.li/Q02ShL_50 #OncologyInnovation #nuclearmedicine #radiopharmaceuticals #CancerTreatment #DMPK #drugdiscovery #drugdevelopment

Did you know that small and large molecules require vastly different bioanalytical techniques? Our latest blog breaks down these differences and explains why understanding them is vital for your preclinical studies. Take advantage of these insights that could streamline your path to regulatory approval. #PharmaceuticalIndustry #DrugDiscovery #Bioanalysis #LargeMolecules https://hubs.li/Q02Q3gk30

Peptide drugs offer high target affinity and specificity but are often challenged by low bioavailability and short circulation times, which can limit their therapeutic effectiveness. Optimizing DMPK properties is key to unlocking their full potential. Join WuXi AppTec and AAPS for an exclusive webinar on peptide DMPK optimization strategies. Learn how our in vitro models, customized sample processing, and expert insights can elevate your peptide drug development from early screening to IND submission. 📅 Date: November 6, 2024 🕒 Time: 11:15 AM - 11:45 AM EST 🔗 Register here: https://hubs.li/Q02Vn2kS0 (free to everyone, but need to register a free account at AAPS) #PeptideDrugs #DMPK #PharmaResearch #DrugDevelopment #Bioavailability #PharmaceuticalScience #INDSubmission

Key benefits of molecular imaging in preclinical research: non-invasive visualization and real-time monitoring of biological processes and early identification of biomarkers that appear before anatomical or functional symptoms manifest. Stay ahead of the curve with WuXi AppTec’s cutting-edge molecular imaging services. https://hubs.li/Q02QMZ9c0 #drugdevelopment #molecularimaging #clinicaltrials #preclinicalstudies #pharma #pharmaceuticals

There’s one day left of AAPS 2024 #PharmSci360, and we still have several posters on display. Be sure to check them out tomorrow, October 23: 💡 Poster by Pei Zhang: Simultaneous Quantification of Multiple ADC Component Concentrations and DAR Profiling with One Aliquot of Plasma in NHP Toxicology Study by Hybrid LC-MS 💡 Poster by Viola Wang: Lumbar Intrathecal Infusion of an siRNA Formulation via Cannulation in Rats Demonstrated Comparable Tissue Distributions and Improved Animal Response as Compared to Non-Cannulated Free-Hand Method 💡 Poster by Li Qu: Development of a Rapid, High Throughput Quantitative Bioanalysis Method for Conjugated Payloads of Protease-Cleavable Antibody-Drug Conjugate (ADC) in Rat Serum Using Automated Immuno-Capture Based UPLC-MS/MS 💡 Poster by Xin Ning: Comparison of the performance of Luminex-based and MSD-based Immunogenicity Assays for Multivalent HPV Vaccines Come to booth 1730 this afternoon for our Happy Hour at 3:00 pm and speak with a subject matter expert in the area of drug development lab testing. We hope to see you there! https://hubs.li/Q02SSLmV0 #American Association of Pharmaceutical Scientists (AAPS) #appscomms

WuXi AppTec’s researchers have closely examined multi-ion channel inhibition assays to determine just how effective they can be. Read more to find out how vital these assays are to the future of drug development. https://hubs.li/Q02QNd470 #drugdevelopment #PharmaceuticalResearch #CardiacSafety